Showing results (291-300 of 9,098) with videos related to
Sort By:
Pageof 910
Cancer Medicine|March 9, 2019
A genetic variant in miR-100 is a protective factor of childhood acute lymphoblastic leukemiaYao Xue, Xiaoyun Yang, Shaoyan Hu, et al.Cancer Medicine|March 9, 2019
Increased LGALS3 expression independently predicts shorter overall survival in patients with the proneural subtype of glioblastomaXia He, Sunfu Zhang, Junchen Chen, et al.Cancer Medicine|March 9, 2019
Clinical validation of an immunohistochemistry-based CanAssist-Breast test for distant recurrence prediction in hormone receptor-positive breast cancer patientsManjiri M Bakre, Charusheila Ramkumar, Arun Kumar Attuluri, et al.Cancer Medicine|February 17, 2021
Association between sex hormones regulation-related SNP rs12233719 and lung cancer risk among never-smoking Chinese womenYing Qian, Li Xie, Lei Li, et al.Cancer Medicine|January 22, 2021
Efficacy and safety of sorafenib plus vitamin K treatment for hepatocellular carcinoma: A phase II, randomized studyYoshimichi Haruna, Takayuki Yakushijin, Seiichi KawamotoCancer Medicine|January 22, 2021
Circ_0008305-mediated miR-660/BAG5 axis contributes to hepatocellular carcinoma tumorigenesisFuguo Yan, Bin Fan, Jianchu Wang, et al.Cancer Medicine|January 25, 2021
R-COMP versus R-CHOP as first-line therapy for diffuse large B-cell lymphoma in patients ≥60 years: Results of a randomized phase 2 study from the Spanish GELTAMO groupJuan-Manuel Sancho, Rubén Fernández-Alvarez, Francisco Gual-Capllonch, et al.Cancer Medicine|February 15, 2021
Polymorphic variants INSIG2 rs6726538, HLA-DRB1 rs9272143, and GCNT1P5 rs7780883 contribute to the susceptibility of cervical cancer in the Bangladeshi womenMd Emtiaz Hasan, Maliha Matin, Md Enamul Haque, et al.Cancer Medicine|February 15, 2021
Anlotinib for previously treated advanced or metastatic esophageal squamous cell carcinoma: A double-blind randomized phase 2 trialJing Huang, Juxiang Xiao, Wentao Fang, et al.Cancer Medicine|February 23, 2021
Does biomarker use in oncology improve clinical trial failure risk? A large-scale analysisJayson L Parker, Sebnem S Kuzulugil, Kirill Pereverzev, et al.Pageof 910